AMLX

#1804
Amylyx Pharmaceuticals, Inc. - Common Stock
14.3 5 USD
+0.91%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
13.95
14.37
Faixa anual
4.71
18.61
Mudança diária
+0.91%
Mudança mensal
-8.19%
Mudança em 6 meses
-2.18%
Mudança anual
+188.73%
Fechamento anterior
14.2 2
Open
14.0 1
Mínimo
13.9 5
High
14.3 7
Volume
666
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas Dividendos
Trimestral Ano
  • Market Capitalization 1.6 B
  • Employee 136
  • Founded 2013
  • CEO N/A
  • Website www.amylyx.com
  • Headquarter Delaware, United States
  • FIGI BBG00DP10YT5
  • Industry Biotecnologia
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
-7.9
Índice preço/fluxo de caixa
—

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Notícias